Homepage
Author:
Allarity Therapeutics, Inc.
Posted Date:
May 5, 2026
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign
Allarity Therapeutics, Inc.
May 5, 2026
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
Allarity Therapeutics, Inc.
April 27, 2026
Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer
Allarity Therapeutics, Inc.
April 23, 2026
Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer
Allarity Therapeutics, Inc.
April 21, 2026
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
Allarity Therapeutics, Inc.
March 31, 2026
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
Allarity Therapeutics, Inc.
March 6, 2026
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need
Allarity Therapeutics, Inc.
February 18, 2026
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment
Allarity Therapeutics, Inc.
February 3, 2026
